shopping cart
nothing in cart
 
browse by subject
new releases
best sellers
sale books
browse by author
browse by publisher
home
about us
upcoming events
Aug 10th - Narrative Therapy Certificate: Actively engage and leave empowered to implement change [SickKids CCMH Learning Institute]
Aug 14th - Deep Summer Retreat [Hugh Smiley]
Sep 4th - The Deepest Kindness: ACT and the Therapeutic Relationship [Ottawa River Psychology Group]
Sep 14th - Integrating EMDR into Your Clinical Practice: Five-Day Intensive in Toronto [Leading Edge Seminars]
Sep 23rd - Supporting the Mental Health Needs of Racialized Young People [SickKids CCMH Learning Institute]
schools agencies and other institutional orders (click here)
Free shipping across Canada for all orders over $50. Please read our Covid-19 statement here.
Join our mailing list! Click here to sign up.
The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, Third Edition
American Psychiatric Association
American Psychiatric Press / Softcover / 2020-09-01 / 0890424691
Psychiatry / Forthcoming
price: $110.95 (may be subject to change)
Not Yet Published

Worldwide, schizophrenia is one of the top 20 causes of disability. The lifetime prevalence of schizophrenia is estimated to be approximately 0.7%, although findings vary depending on the study location, demographic characteristics of the sample, the approach adopted for case finding, the method employed for diagnostic confirmation, and the diagnostic criteria used. Economic burdens associated with schizophrenia are high, with an estimated cost of more than $150 billion annually in the United States on the basis of 2013 data. Additional research since the second edition of the guideline has expanded our knowledge of the effective and evidence-based interventions available to help reduce the mortality, morbidity, and significant psychosocial and health consequences of this important psychiatric condition.

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia seeks to reduce these substantial psychosocial and public health consequences for the individuals affected by schizophrenia. The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these recommendations into clinical practice, with the goal of improving the quality of care and treatment outcomes for patients with schizophrenia.

Table of Contents:

Acronyms/Abbreviations
Introduction
Chapter 1. Rationale
Chapter 2. Guideline Statement Summary
Chapter 3. Guideline Statements and Implementation
Chapter 4. Pharmacotherapy
Chapter 5. Review of Available Guidelines from Other Organizations
Chapter 6. Psychosocial Interventions
Chapter 7. Areas for Further Research in Individuals with Schizophrenia
Chapter 8. Guideline Development Process
Glossary of Terms
References
Disclosures
Individuals and Organizations That Submitted Comments
Appendix A. Clinical Questions
Appendix B. Search Strategies, Study Selection, and Search Results
Appendix C. Review of Research Evidence Supporting Guideline Statements
Appendix D. Strength of Evidence

Caversham Booksellers
98 Harbord St, Toronto, ON M5S 1G6 Canada
(click for map and directions)
All prices in $cdn
Copyright 2020

Phone toll-free (800) 361-6120
Tel (416) 944-0962 | Fax (416) 944-0963
E-mail [email protected]
Hours: 9-6 Mon-Sat / Closed Sunday (EST)

search
Click here to read previous issues.
other lists
Forthcoming
Psychiatry